Lorazepam Dosing for Status Epilepticus
For status epilepticus in adults, administer lorazepam 0.1 mg/kg IV (maximum 4 mg per dose) at a rate of 2 mg/min; for children, use 0.05-0.1 mg/kg IV (maximum 4 mg per dose). If seizures persist after 10-15 minutes, repeat the same dose once.
Adult Dosing
The FDA-approved dosing for adults (≥18 years) is 4 mg IV given slowly at 2 mg/min 1. This can be repeated once after a 10-15 minute observation period if seizures continue or recur, for a maximum total dose of 8 mg 1, 2.
When expressed as weight-based dosing, the recommended dose is 0.05-0.1 mg/kg IV (maximum 4 mg per dose), which can be repeated every 10-15 minutes as needed 2. The 2008 AAP Pediatrics guideline confirms this dosing applies to both adults and children 2.
Critical evidence supporting 4 mg dosing: A 2023 retrospective study of 120 adult patients (all >40 kg) demonstrated that patients receiving less than 4 mg had significantly higher progression to refractory status epilepticus (87% vs 62%, p=0.03) compared to those receiving the full 4 mg dose 3. This strongly supports using the maximum recommended dose rather than underdosing.
Pediatric Dosing
For children, use 0.05-0.1 mg/kg IV/IM (maximum 4 mg per dose), repeatable every 10-15 minutes if seizures continue 2. The 2019 CAR T-cell therapy guideline specifies different dosing for convulsive versus non-convulsive status epilepticus in pediatrics 4:
- Convulsive status epilepticus: 0.1 mg/kg (maximum 2 mg) IV, repeat after at least 1 minute (maximum 2 doses)
- Non-convulsive status epilepticus: 0.05 mg/kg (maximum 1 mg) IV, repeat every 5 minutes (maximum 4 doses)
Important caveat: The FDA label notes that safety in pediatric patients has not been fully established, though the drug is widely used in this population 1.
Administration Details
- Rate of administration: Give slowly at 2 mg/min to minimize respiratory depression risk 1, 2
- Dilution required: Must dilute with equal volume of compatible diluent before IV use 1
- Route preference: IV is strongly preferred over IM for status epilepticus, though IM may be used when IV access is unavailable 1
Critical Safety Considerations
Respiratory support must be immediately available before administering lorazepam 1. The most important risk is respiratory depression, particularly when combined with other sedatives 2. Equipment for airway management and ventilatory support should be at bedside.
Monitor for:
- Respiratory depression (most critical)
- Excessive sedation (prolonged duration of action)
- Hypotension
- Need for assisted ventilation (occurs in approximately 16-18% of patients) 5
Comparative Efficacy
A 2001 landmark prehospital trial (n=205) showed lorazepam terminated status epilepticus in 59.1% of patients versus 42.6% for diazepam and 21.1% for placebo (p=0.001) 6. However, a 2014 pediatric ED trial (n=273) found no significant difference between lorazepam and diazepam (72.9% vs 72.1% efficacy, respectively) 5.
The 2019 ESETT trial demonstrated that lorazepam, fosphenytoin, and valproate had similar efficacy as second-line agents after benzodiazepines (all approximately 45-47% response rates) 7.
Clinical Pitfalls to Avoid
Underdosing is common and harmful: Many clinicians give less than 4 mg in adults, which significantly increases progression to refractory status epilepticus 3
Don't delay for weight calculation: In adults, give the full 4 mg dose immediately rather than spending time calculating weight-based dosing 1
Avoid intra-arterial injection: Inject slowly with repeated aspiration; stop immediately if patient complains of pain during injection 1
Don't use as monotherapy: Lorazepam is only the initial step; prepare to administer second-line agents (fosphenytoin, valproate, or levetiracetam) if seizures persist beyond 10 minutes 1
Benzyl alcohol warning: The injectable formulation contains benzyl alcohol, which requires caution in neonates 1